Testing effectiveness (Phase 2)Ended earlyNCT04700280
What this trial is testing
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
Who this might be right for
Primary Sjögren Syndrome
Lakefront Biotherapeutics NV 31